Capricor Therapeutics Inc (OTCMKTS:CAPR) announced its earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02, Bloomberg Earnings reports. The company had revenue of $1 million for the quarter, compared to the consensus estimate of $1.10 million.
Shares of Capricor Therapeutics (CAPR) opened at 1.05 on Friday. The stock has a 50 day moving average of $0.96 and a 200 day moving average of $2.01. Capricor Therapeutics has a 52 week low of $0.63 and a 52 week high of $4.09. The firm’s market cap is $23.72 million.
Several equities research analysts have issued reports on CAPR shares. Zacks Investment Research lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. HC Wainwright set a $2.00 price target on shares of Capricor Therapeutics and gave the company a “buy” rating in a report on Tuesday, July 18th. ValuEngine lowered shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $2.15 price target on shares of Capricor Therapeutics in a report on Saturday, July 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $4.91.
A hedge fund recently raised its stake in Capricor Therapeutics stock. Virtu KCG Holdings LLC increased its position in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 571.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 179,301 shares of the biotechnology company’s stock after buying an additional 152,614 shares during the period. Virtu KCG Holdings LLC owned 0.79% of Capricor Therapeutics worth $149,000 at the end of the most recent reporting period.
About Capricor Therapeutics
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
What are top analysts saying about Capricor Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Capricor Therapeutics Inc and related companies.